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E-mail: jzurita@zuritalaboratorios.comIntroductionContinued improvement of techniques for identiﬁcation of
mycobacteria has produced a resurgence of interest in diseases
caused by species other than Mycobacterium tuberculosis.
Currently there are more than 150 species of nontuberculous
mycobacteria, and more than half are considered deﬁnite or
potential pathogens in humans [1].w Microbe and New Infect 2016; 10: 112–115
w Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of
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p://dx.doi.org/10.1016/j.nmni.2016.01.006Mycobacterium monacense is rapidly growing nontuberculous
mycobacteria, ﬁrst described in 2006 by Reischl et al. [2]. The
name monacense come from Monacum, the Latin name of the
German city of Munich, where the ﬁrst strain was isolated.
Subsequently ﬁve additional reports [3–7] have been published
that describe infection by this new species. Here we report the
ﬁrst case of M. monacense associated with chronic nodular
vasculitis infecting a woman in Ecuador.
Erythema induratum was previously described in association
with tuberculosis in the middle of the 19th century. The clinical
picture is characterized by tender violaceous nodules and
plaques most commonly affecting the posterior lower legs
(usually calves), with the shins involved less often. The nodules
are tender and erythematous (those may ulcerate with bluish
borders), and cold weather may be a precipitating factor.
About half of the patients have a past or present history of
tuberculosis. This is most often pulmonary tuberculosis, with
cervical lymphadenopathy second. Erythema induratum often
remains undiagnosed or misdiagnosed because it is often
mistaken for other types of chronic nodules of the lower
extremities.Case ReportA 29-year-old woman with a previous clinical diagnosis of er-
ythema nodosum 4 months before was admitted to hospital
with chronic recurrent nodular lesions in both legs associated
with moderate pain and erythema. She had previously received
topical steroid injections in the lesions, with partial improve-
ment. Four days before admission, she noted a new nodular
lesion on the anterior aspect of her left knee.
The skin lesions were tender erythematous nodules
approximately 3 cm in diameter located on the anterior and
posterior aspects both legs (Fig. 1). An ulcerated nodule with an
abscess was present on the medial aspect of her left knee. At
admission, here complete blood count was 8580 leucocytes
with 50.8% neutrophils, hemoglobin 12.4 g/dL and C-reactive
protein 68.99 mg/dL. Because of the possibility of erythema
induratum, a chest X-ray was conducted, which revealed no
pathologic lesions on the lungs. Serology for hepatitis B and C
virus was negative.
A deep biopsy of the nodular lesion was performed; the
biopsy sample was sent for histopathologic, bacteriologic and
mycobacteriologic diagnosis. Results revealed lobular pan-
niculitis consistent with nodular vasculitis (Fig. 1). Ziehl-
Neelsen staining, performed on a direct biopsy sample, was
negative for acid-fast bacilli.European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
FIG. 1. (A) Tender nodular lesions present on anterior aspects of legs. (B) Biopsy sample of nodular lesion revealing lobular panniculitis and lym-
phocytic vasculitis.
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agar, MacConkey agar, Lowenstein-Jensen media and Myco-
bacteria Growth Indicator Tube (MGIT). After 5 days’ growth
in MGIT and after 7 days evidence of growth was observed on
agar plates as well on Lowenstein-Jensen media but not on
MacConkey agar; a rapid test for SD Bioline TB Ag MPT64 wasTABLE 1. Review of Mycobacterium monacense
Year of
isolation
Age
(years) Country
Clinical or underlying
condition Sample
1998 80 Germany Multifocal lung carcinoma
and insulin-dependent
diabetes mellitus
Bronchial
lavage
2000–2005 11 Italy Fistula on his right thigh from
accidental deep penetration
of screwdriver
Fistula
2000–2005 31 Italy Bronchopneumonitis Sputum
2000–2005 82 Italy Suspected lung cancer Sputum
2001–2006 26 Brazil Meningitis Cerebrospinal ﬂuid
2007 36 China Car accident in Germany.
During initial examination of
broken clavicle and radius,
received thoracic computed
tomographic scan revealing
large tumor in upper lobe of
his lung highly suspicious for
tuberculosis
Bronchoalveolar
lavage sample
and sputum
2007 59 USA Non– insulin dependent
Diabetes mellitus presented
with pain, swelling and
recurrent pustules of
left thumb
Tissue biopsy
2011 43 India Diabetes Sputum
2012 57 Iran Chronic pulmonary disease Sputum
aClarithromycin 500 mg twice a day and levoﬂoxacin 500 mg twice a day were initiated 2 mon
emergency room. Clinical response was discernible within 2 weeks; pain began to resolve, a
asymptomatic, with minimal swelling and fading erythema.
bAfter the initial 45 days of antituberculosis therapy and the following 45 days of antimicrob
patient’s general condition improved.
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This is an open access artiperformed, with negative results (Standard Diagnostics,
Gyeonggi-do, Korea). Cultures performed using solid media
revealed yellow-pigmented colonies. Identiﬁcation by matrix-
assisted laser desorption/ionization time-of-ﬂight mass spec-
trometry (MALDI-TOF; Bruker Daltonics, Leipzig, Germany)
was performed identifying the colonies as MycobacteriumHIV status
Acid-
fast
smear Treatment Follow-up Reference
Unknown Unknown Unknown Unknown [2]
Unknown Unknown Unknown Unknown [2]
Unknown Unknown Unknown Unknown [2]
Unknown Unknown Unknown Unknown [2]
Positive Unknown Unknown Unknown [3]
Negative Negative Unknown Lost to follow-up [4]
Unknown Unknown Clarithromycin
+ levoﬂoxacina
At 14-month
follow-up,
complete
resolution had
occurred and
hand function was
normal
[5]
Negative Negative Unknown Lost to follow-up [6]
Unknown Positive Antituberculosis
ﬁrst, amikacin
+ ciproﬂoxacinb
24 months later,
patient did not
experience
relapse
[7]
ths after symptoms were ﬁrst noted and 1 month after the patient was ﬁrst seen in the
nd erythema and swelling decreased. By 6 weeks of therapy, the patient was
ial therapy of nontuberculous pulmonary infection (amikacin plus ciproﬂoxacin), the
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Mycobacteria Library 2.0 reference spectra using MALDI Bio-
typer 3.1 software (Bruker). PCR restriction enzyme analysis
(PRA)-hsp65 was performed as described elsewhere [8]. The
PRA-hsp65 assay also identiﬁed the isolate as M. monacense.
The sequencing of hsp65 and rpoB genes conﬁrmed the identity
of the M. monacense isolate. The analysis of the nucleotide se-
quences were performed with MEGA 6 6.06 and National
Center for Biotechnology Information BLAST (Basic Local
Alignment Search Tool; http://blast.ncbi.nlm.nih.gov/). The
hsp65 and rpoB nucleotide sequences were deposited into
GenBank with the following accession numbers: hsp65,
KU361326l and rpoB, KU361327.
Susceptibility testing was performed using the rapid growing
mycobacteria plate (Sensititre RAPMYCOI; Thermo Scientiﬁc,
Waltham, MA, USA), showing the following breakpoints (mg/L):
trimethoprim/sulfamethoxazole 0.25/4.75, linezolid 1, cip-
roﬂoxacin 1, imipenem 4, moxiﬂoxacin 0.25, cefepime 8,
cefoxitin 64, amoxicillin/clavulanic acid 2/1, amikacin 1,
ceftriaxone 4, doxycycline 0.12, minocycline 1, tigecycline
0.030, tobramycin 16 and clarithromycin 8. No interpretation
of the breakpoints was performed because there are no
breakpoints available for M. monancense in the international
guidelines. In this case, we also performed an Etest, which
obtained the same results as RAPMYCOI, which indicates that
the Etest may be helpful when access to microdilution is not
possible.
The patient received a short course of oral steroids
pending the microbiologic and pathologic results, with partial
relief of her symptoms. The patient was informed of the
diagnosis of Mycobacterium monacense by phone, with the
recommendation that she go to hospital for the treatment to
be adjusted, but the patient did not return for a follow-up
consultation.DiscussionThe ﬁrst description of the species M. monacense was made in
2006 in three nonrelated respiratory samples and one tissue
biopsy sample from a posttraumatic wound infection [2]. To
our knowledge, there are ﬁve additional reports on the isola-
tion of M. monacense in clinical samples after the initial
description (Table 1). In six respiratory samples [2,4,6,7], the
clinical signiﬁcance of the isolation could not be proved in
three. In the two soft tissue infections, the clinical relevance
was clariﬁed in one of the cases [5].
Rapidly growing nontuberculous mycobacteria are an
increasingly recognized cause of skin and soft tissue infections,
with M. abscessus, M. fortuitum and M. chelonae being the mostNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licecommon species involved. According to the clinical history, the
nodular lesions preceded the topical steroid injections on the
legs, suggesting that M. monacense caused a secondary infection
of the lesions, with the port of entry being the steroid in-
jections. Because the patient was lost to follow-up we were
unable to perform further evaluation.
Nowadays, MALDI-TOF is a good tool for the diagnosis of
rapid growing mycobacteria as long as the bacteria is included in
the software database. Further, PCR restriction enzyme analysis
has limitations, as sometimes it is not possible to distinguish
among species. For these reasons, we consider that sequencing
is a must when identifying rapidly growing mycobacteria [9]. In
this study, the three techniques we used veriﬁed the ﬁrst
identiﬁcation, conﬁrming the results, but this is not always the
case for noncommon rapidly growing mycobacteria or those
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